ArticleCurrent treatment options in infectious diseases2015
Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery.
Article in Current treatment options in infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Social-Cognitive and Identity-Related Factors Promoting Pre-exposure Prophylaxis (PrEP) Uptake Among Bisexual Men.AIDS and behavior · 2026Article
- Leveraging A Digital Pill System to Understand Prevention-Effective Adherence to Oral Hiv Pre-Exposure Prophylaxis Among Men Who Have Sex with Men with Substance Use.AIDS and behavior · 2024Article
- Pre-Exposure Prophylaxis and HIV Prevention Among Key Populations in Nigeria.International journal of MCH and AIDS · 2024Article
- Real-World Implementation Challenges Associated with a Digital Pill System to Measure Adherence to HIV Pre-Exposure Prophylaxis from Two Studies of Men Who Have Sex With Men.Proceedings of the ... Annual Hawaii International Conference on System Sciences. Annual Hawaii International Conference on System Sciences · 2024Article
- Article
- Pre-exposure Prophylaxis (PrEP) Information on Instagram: Content Analysis.JMIR public health and surveillance · 2021Article
- Design and Delivery of Real-Time Adherence Data to Men Who Have Sex with Men Using Antiretroviral Pre-exposure Prophylaxis via an Ingestible Electronic Sensor.AIDS and behavior · 2021Article
- Article
- Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation.Current infectious disease reports · 2019Review
- A Case Report: Tragic Death in a Young Patient with Human Immunodeficiency Virus Due to Cryptococcal Meningitis.Cureus · 2019Article
- Improving PrEP Implementation Through Multilevel Interventions: A Synthesis of the Literature.AIDS and behavior · 2018Review
- Progress in HIV vaccine development.Human vaccines & immunotherapeutics · 2017Review
- Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Brief Report: PrEP Uptake, Adherence, and Discontinuation Among California YMSM Using Geosocial Networking Applications.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa.Journal of the International AIDS Society · 2016Article
- The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.Nanomedicine (London, England) · 2015Review
- mRNA-based vaccine technology for HIV.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pre-exposure prophylaxis (PrEP) is an effective and evidence-based HIV-prevention option and is recommended for individuals with substantial risk for HIV infection [1]. Randomized controlled trials have demonstrated that daily oral PrEP dramatically reduces the risk of HIV infection when it is taken as directed. Concerns regarding widespread emergence of antiretroviral resistance attributable to PrEP and behavioral disinhibition have to date not been observed in clinical trials and open-label demonstration projects. PrEP has great potential as part of an HIV risk reduction strategy and barriers to wider implementation including community education, prescriber availability, and elimination of financial barriers should be aggressively pursued. Adherence is critical to PrEP efficacy and has varied across study populations; developing and refining ways of measuring and supporting adherence is essential to the success of PrEP. Evaluation of long-acting medications and alternative formulations for PrEP is underway and may lead to the wider implementation and impact of PrEP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.